Paul McDonagh

Chief Scientific Officer and Founder @ Archetype Therapeutics, Inc. | AI-native drug discovery

Role
Chief Scientific Officer and Founder at Archetype Therapeutics, Inc
Location
Cambridge, MA, US
LinkedIn followers
500 followers

About Paul McDonagh

With over two decades of experience in bioinformatics, computational biology, and molecular biology, I am currently the Chief Scientific Officer at Archetype Therapeutics. My mission is to bridge the translational gap in drug discovery by leveraging AI, chemoinformatics, and real-world evidence to revolutionize therapeutic development. Passionate about utilizing clinicogenomic data to connect disease biology with clinical outcomes, I bring diverse perspectives and innovative strategies to our team. At Archetype Therapeutics, I lead efforts to develop an AI-native drug discovery platform that simulates therapeutic molecule testing end-to-end, accelerating breakthroughs in patient care. By integrating cutting-edge technologies with deep scientific expertise, our team is advancing treatments tailored to specific disease cohorts. My work is grounded in collaboration and a commitment to transforming patients\' lives.

Experience

  1. Chief Scientific Officer and Founder

    Archetype Therapeutics, Inc

    Jan 2023 — Present · Boston, MA, US

    AI-native drug discovery and development. See: co-founders have spent over two decades working with world-class teams in pharmaceutical companies and analytics startups with a focus on utilizing patient clinicogenomic data to characterize disease and to link disease-specific biology with clinical outcomes. What has been missing is the ability to test existing and novel therapeutic molecules in silico end-to-end from a proposed molecule to a clinical readout in a patient cohort of interest. Finally, leveraging advances in AI, chemoinformatic tools, and real-world evidence (RWE) patient data, we have in Archetype built a platform to bridge the translational gap between drug discovery and patient disease outcomes. We have leveraged this platform to discover and repurpose small molecule therapeutics in lung cancer, prostate cancer, melanoma, and IPF. i•••@archetypetx.com

Education

  • University of Leicester

    Ph.D, Biochemistry and Protein structure

  • University of Leicester

    B.Sc, Biological Science

    1989 — 1993

  • The Wharton School

    Certificate, Entrepreneurship/Entrepreneurial Studies

    2019

  • University of Washington

    Cert, C Programming

  • University of Washington

    Cert, C++ programming

Skills

  • Objective-C
  • Biomarkers
  • R
  • Capacity Planning
  • Biomarker Discovery
  • Java
  • Databases
  • Biostatistics
  • Bayesian Statistics
  • Bayesian Networks
  • Cross-Functional Team Leadership
  • C/C++ Stl
  • Hadoop
  • Microarray Analysis
  • Amazon Web Services (Aws)
  • High Performance Computing
  • Biotechnology
  • Project Management
  • Systems Biology
  • Artificial Intelligence
  • Genetics
  • Bioinformatics
  • Mapreduce
  • Functional Genomics
  • Science
  • Life Sciences
  • Bayesi
  • Software Development
  • Machine Learning
  • Dna Sequencing
  • Personalized Medicine
  • Computational Biology
  • Ios Development
  • Molecular Biology

Find verified contacts for anyone on LinkedIn

Unifers gives sales teams verified emails and direct dials, enriched profiles, and outreach that lands in the inbox.

Free plan included · No credit card required

This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.

Paul McDonagh — Chief Scientific Officer and Founder at Archetype Therapeutics, Inc in Cambridge, MA, US | Unifers